The cobas® 4800 System can help you increase lab efficiency by providing you with a robust option to enable the consolidation of your testing needs. This solution can significantly reduce costs, improve operational efficiencies and maximize resources.
References:
1. Report on the Burden of Endemic Health Care-Associated Infection Worldwide. World Health Organization (WHO) Website.
2. Sexually transmitted infections. World Health Organization (WHO) Website. http://www.who.int/topics/sexually_transmitted_infections/en. Accessed October 13, 2015. http://apps.who.int/iris/bitstream/10665/80135/1/9789241501507_eng.pdf. Accessed October 13, 2015.
3. Howerton D, Anderson N, Bosse D, Granade S, Westbrook G. Good laboratory practices for waived testing sites: survey findings from testing sites holding a certificate of waiver under the clinical laboratory improvement amendments of 1988 and recommendations for promoting quality testing. MMWR Recomm Rep. 2005;54:1-25.
4. Data on file. www.rochemicrobiologytests.com
Detects a broad array of toxinotypes and ribotypes, targeting a specific C. difficile toxin gene directly from uniformed stool samples
Delivers results with high specificity and sensitivity to identify colonized patients
Reduces the risk of false positive results with the AmpErase enzyme, while testing CT and NG simultaneously in the same sample
Offers highly sensitive and specific results in the direct detection of HSV 1 and HSV 2 DNA in clinical samples
Page last updated: 10/22/2015
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. The cobas® MRSA/SA, Cdiff and HSV 1 and 2 tests are not available in the US. Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.
